351 related articles for article (PubMed ID: 1962909)
1. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
Shimotori T; Sakuragawa N
Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
[TBL] [Abstract][Full Text] [Related]
2. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
Ofosu FA; Smith LM; Anvari N; Blajchman MA
Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms for the anticoagulant effect of heparin and related polysaccharides.
Ofosu FA
Nouv Rev Fr Hematol (1978); 1988; 30(3):155-60. PubMed ID: 2971155
[TBL] [Abstract][Full Text] [Related]
4. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
Peyrou V; Béguin S; Boneu B; Hemker HC
Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
[TBL] [Abstract][Full Text] [Related]
5. Study of low molecular weight heparin effect on the relation between anticoagulant activity and antithrombin III affinity.
Hamano S; Nishiyama M; Kikuchi S; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
Thromb Res; 1992 May; 66(4):299-307. PubMed ID: 1329257
[TBL] [Abstract][Full Text] [Related]
6. The effect of calcium chloride on anti-Xa activity of heparin and its molecular weight fractions.
Barrowcliffe TW; Le Shirley Y
Thromb Haemost; 1989 Nov; 62(3):950-4. PubMed ID: 2556814
[TBL] [Abstract][Full Text] [Related]
7. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
Bohner J; von Pape KW; Blaurock M
Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
[TBL] [Abstract][Full Text] [Related]
8. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
Brieger D; Dawes J
Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
[TBL] [Abstract][Full Text] [Related]
9. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II.
Tollefsen DM; Sugimori T; Maimone MM
Semin Thromb Hemost; 1990 Oct; 16 Suppl():66-70. PubMed ID: 1962908
[TBL] [Abstract][Full Text] [Related]
10. Effects of sulfation on antithrombin-thrombin/factor Xa interactions in semisynthetic low molecular weight heparins.
Sissi C; Naggi A; Torri G; Palumbo M
Semin Thromb Hemost; 2001 Oct; 27(5):483-7. PubMed ID: 11668417
[TBL] [Abstract][Full Text] [Related]
11. Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
Jeske W; Fareed J
Semin Thromb Hemost; 1993; 19 Suppl 1():241-7. PubMed ID: 8362268
[TBL] [Abstract][Full Text] [Related]
12. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
[TBL] [Abstract][Full Text] [Related]
13. [Effect of heparin cofactor II on the antithrombin III activities measured by thrombin methods or factor Xa methods--fundamental studies and clinical studies using the plasma of pregnant women].
Akai Y; Shiga S; Tohyama K; Shimatsu A; Ichiyama S
Rinsho Byori; 2000 Sep; 48(9):867-71. PubMed ID: 11051806
[TBL] [Abstract][Full Text] [Related]
14. The mode of action of CY216 and CY222 in plasma.
Béguin S; Wielders S; Lormeau JC; Hemker HC
Thromb Haemost; 1992 Jan; 67(1):33-41. PubMed ID: 1319616
[TBL] [Abstract][Full Text] [Related]
15. An algal sulfated galactan has an unusual dual effect on venous thrombosis due to activation of factor XII and inhibition of the coagulation proteases.
Melo FR; Mourão PA
Thromb Haemost; 2008 Mar; 99(3):531-8. PubMed ID: 18327401
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological activities of heparins obtained from different tissues: enrichment of heparin fractions with high lipoprotein lipase, antihemolytic and anticoagulant activities by molecular sieving and antithrombin III affinity chromatography.
Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP
J Pharmacol Exp Ther; 1982 Feb; 220(2):406-10. PubMed ID: 7057400
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
Meddahi S; Bara L; Fessi H; Samama MM
Blood Coagul Fibrinolysis; 2000 Jan; 11(1):51-9. PubMed ID: 10691099
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological profile of the low molecular weight heparin 21-23 in man: anticoagulant, lipolytic and protamine reversible effects.
Harenberg J; Stehle G; Dempfle CE; von Hodenberg E; Heene DL
Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):967-80. PubMed ID: 2483715
[TBL] [Abstract][Full Text] [Related]
19. The effects of human thrombomodulin on the inactivation of thrombin by its serum inhibitors.
Thompson EA; Salem HH
Thromb Haemost; 1987 Oct; 58(3):806-10. PubMed ID: 2829375
[TBL] [Abstract][Full Text] [Related]
20. [The antithrombin action of stichopus japonicus acid mucopolysaccharide (Sjamp) is mediated by heparin cofactor II].
Zhang G
Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):126-9. PubMed ID: 15622771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
